SCHEMBL25517567

SCHEMBL25517567

OC(Cc1cccc(Cl)c1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.65
▸ PNMT P11086 2/20 0.55
▸ SLC6A2 P23975 1/20 0.52
▸ SLC6A4 P31645 1/20 0.52
▸ IDO1 P14902 1/20 0.49
▸ TDO2 P48775 1/20 0.49
▸ TACR1 P25103 2/20 0.48
▸ SIGMAR1 Q99720 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ GRIN2B Q13224 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ADRB3 P13945 1/20 0.45
▸ HSD17B2 P37059 1/20 0.45
▸ ACP3 P15309 1/20 0.45
▸ HTR3E A5X5Y0 1/20 0.44
▸ HTR3B O95264 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25518189 0.91 PNMT (0.56) LMNAPNMTSLC6A2SLC6A4TSHR
SCHEMBL30615772 0.91 PNMT (0.56) LMNAPNMTSLC6A2SLC6A4TSHR
SCHEMBL9701276 0.89 LMNA (0.56) LMNAPNMTSLC6A2SLC6A4IDO1
SCHEMBL11552641 0.86 LMNA (0.52) LMNAACP3
SCHEMBL4294493 0.80 PNMT (0.68) LMNAPNMTIDO1TSHRRECQL
SCHEMBL7005600 0.80 PNMT (0.53) LMNAPNMTSLC6A2SLC6A4IDO1
SCHEMBL949577 0.80 PNMT (0.62) LMNAPNMTSLC6A2SLC6A4IDO1
SCHEMBL22394811 0.80 MEN1 (0.56) LMNAPNMTSLC6A2SLC6A4IDO1
SCHEMBL125923 0.80 LMNA (0.58) LMNASLC6A2SLC6A4ACP3
SCHEMBL4355212 0.80 LMNA (0.58) LMNASLC6A2SLC6A4ACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 — — US disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 — — US disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 — — US disclosed
EP-4132944-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION Cocrystal Pharma, Inc. (US) 2023-02-15 — — EP disclosed
CN-115698035-A Inhibitors of norovirus and coronavirus replication 共晶制药公司 2023-02-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION VIM, ACE, ACE2 LMNA 2116/4885PNMT 259/4885SLC6A2 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback